Your session is about to expire
← Back to Search
Pharmacogenomics
Pharmacogenomic Testing for Cancer Support Care
N/A
Waitlist Available
Led By Jai Patel, PhD
Research Sponsored by Jai Patel
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 21, 42, 63 and 84 days after the baseline visit
Awards & highlights
Study Summary
This trial will test whether using genetic information to guide prescribing decisions for pain and depression medications leads to better symptom control and quality of life for cancer patients.
Who is the study for?
This trial is for adults over 18 with blood or solid tumor cancers experiencing moderate to high pain or depression. They must consent to personal health info release, provide a cheek sample for genetic testing, and agree to follow-up visits in the palliative medicine clinic.Check my eligibility
What is being tested?
The study tests if using pharmacogenomic (PGx) testing—analyzing how genes affect a person's response to drugs—to guide medication choices can better manage pain and depression in cancer patients compared to past standard treatments.See study design
What are the potential side effects?
Since this trial focuses on personalized drug prescribing based on genetic testing, side effects will vary depending on the medications prescribed. Common side effects may include drowsiness, nausea, dry mouth, or other typical reactions to pain and antidepressant medications.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 21, 42, 63 and 84 days after the baseline visit
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~21, 42, 63 and 84 days after the baseline visit
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Utilization of PGx results
Secondary outcome measures
Compare Health Care Utilization
Depression Scores Impact
Pain Scores Impact
+1 moreOther outcome measures
Frequency of Actionable Genotypes
Frequency of Drug/Gene Interactions
Types of New Medications Prescribed
Trial Design
1Treatment groups
Experimental Treatment
Group I: Pharmacogenomic TestingExperimental Treatment1 Intervention
A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
Find a Location
Who is running the clinical trial?
Jai PatelLead Sponsor
1 Previous Clinical Trials
75 Total Patients Enrolled
Wake Forest University Health SciencesLead Sponsor
1,240 Previous Clinical Trials
1,004,137 Total Patients Enrolled
22 Trials studying Pain
2,387 Patients Enrolled for Pain
Jai Patel, PhDPrincipal InvestigatorWake Forest University Health Sciences
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Pharmacogenomic Testing
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger